Obsidian Therapeutics

Share on: 
Business Area(s): 

Developing controllable cell and gene therapies. Obsidian’s proprietary cytoDRiVE™ platform provides a technology to develop cell and gene therapies in which the level and timing of protein activity are fully controlled in a dose-dependent manner by an FDA-approved small molecule drugs.

Cambridge MA
United States